Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Leask

Showing results (1-10 of 221) with videos related to

Pageof 23
Sort By:
Journal of Cell Communication and Signaling|May 15, 2020
COVID-19: is fibrosis the killer?Andrew Leask
Journal of Cell Communication and Signaling|April 13, 2011
Will o' the wisp: CCN4 as a novel molecular target in osteoarthritisAndrew Leask
The Journal of Investigative Dermatology|April 14, 2012
Toward personalized medicine in scleroderma: classification of scleroderma patients into stable "inflammatory" and "fibrotic" subgroupsAndrew Leask
Journal of Cell Communication and Signaling|July 13, 2011
Eureka! Ets a target for fibrosis!Andrew Leask
Journal of Cell Communication and Signaling|November 16, 2011
Meeting report: novel targets for cancer and connective tissues diseasesAndrew Leask
Journal of Cell Communication and Signaling|February 19, 2009
Hijacking ZIP codes: posttanscriptional regulation of CCN2 by nucleophosminAndrew Leask
Circulation Research|June 12, 2010
Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activationAndrew Leask
Fibrogenesis & Tissue Repair|May 29, 2010
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitmentAndrew Leask
Journal of Cell Communication and Signaling|May 29, 2009
Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2Andrew Leask
Journal of Cell Communication and Signaling|November 11, 2010
Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2Andrew Leask
Pageof 23

Showing results (1-10 of 221) with videos related to

Sort By:
Pageof 23
Journal of Cell Communication and Signaling|May 15, 2020
COVID-19: is fibrosis the killer?Andrew Leask
Journal of Cell Communication and Signaling|April 13, 2011
Will o' the wisp: CCN4 as a novel molecular target in osteoarthritisAndrew Leask
The Journal of Investigative Dermatology|April 14, 2012
Toward personalized medicine in scleroderma: classification of scleroderma patients into stable "inflammatory" and "fibrotic" subgroupsAndrew Leask
Journal of Cell Communication and Signaling|July 13, 2011
Eureka! Ets a target for fibrosis!Andrew Leask
Journal of Cell Communication and Signaling|November 16, 2011
Meeting report: novel targets for cancer and connective tissues diseasesAndrew Leask
Journal of Cell Communication and Signaling|February 19, 2009
Hijacking ZIP codes: posttanscriptional regulation of CCN2 by nucleophosminAndrew Leask
Circulation Research|June 12, 2010
Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activationAndrew Leask
Fibrogenesis & Tissue Repair|May 29, 2010
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitmentAndrew Leask
Journal of Cell Communication and Signaling|May 29, 2009
Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2Andrew Leask
Journal of Cell Communication and Signaling|November 11, 2010
Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2Andrew Leask
Pageof 23